Lv1
40 积分 2020-12-31 加入
From challenges to solutions: A review of fourth-generation EGFR tyrosine kinase inhibitors to overcome the C797S triple mutation in non-small cell lung cancer
29天前
已完结
Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor
4个月前
已完结
SMARCA2 protein: Structure, function and perspectives of drug design
5个月前
已完结
Discovery of FHD-286, a First-in-Class, Orally Bioavailable, Allosteric Dual Inhibitor of the Brahma Homologue (BRM) and Brahma-Related Gene 1 (BRG1) ATPase Activity for the Treatment of SWItch/Sucrose Non-Fermentable (SWI/SNF) Dependent Cancers
5个月前
已完结
An Expedient Approach for the Synthesis of TAM and MET Receptor Kinase Inhibitor’s Core (R)-2-((4-(4-Amino-2-fluorophenoxy)-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)amino)propan-1-ol
6个月前
已完结
Incidence of grade 3-4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis
6个月前
已完结
PARP Inhibitors in Metastatic Prostate Cancer: A Comprehensive Systematic Review and Meta-analysis of Existing Evidence
6个月前
已完结
Efficacy and safety of PARP inhibitors in prostate cancer: An umbrella review of systematic reviews and meta-analyses
6个月前
已完结
Clinical pharmacology and therapeutic applications of talazoparib: a comprehensive review
6个月前
已完结
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
6个月前
已完结
皖公网安备34019202002308
